Table 1.
Rituximab | Ofatumumab | Obinutuzumab | |
---|---|---|---|
Antibody type | Type I | Type I | Type II |
Format | Chimeric | Humanized | Humanized |
CD20 binding site | Large loop | Large and small loops, closer to cell membrane | Large loop |
Localization to lipid rafts | Yes | Yes | No |
Complement-dependent cytotoxicity | High | High | Low |
Antibody-dependent cellular cytotoxicity | Low | Low | High |
Direct cell death | Low | Low | High |